Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years, with the licensing of more than 15 novel and highly effective disease-modifying therapies (DMTs) to treat the disease. In this new complex scenario, an update of the previous therapeutic guidelines published by the American Academy of Neurology (AAN) in 2002 is needed for an appropriate and effective use of the old and new agents in clinical practice.
Complexity of MS management in the current treatment era
Trojano, Maria
2018-01-01
Abstract
Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years, with the licensing of more than 15 novel and highly effective disease-modifying therapies (DMTs) to treat the disease. In this new complex scenario, an update of the previous therapeutic guidelines published by the American Academy of Neurology (AAN) in 2002 is needed for an appropriate and effective use of the old and new agents in clinical practice.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
chitnis2018.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
125.64 kB
Formato
Adobe PDF
|
125.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
